

## Corrigendum

*Ther Adv Med Oncol*

2018, Vol. 10: 1


DOI: 10.1177/  
1758835918810116

© The Author(s), 2018.  
Article reuse guidelines:  
[sagepub.com/journals-  
permissions](http://sagepub.com/journals-permissions)

Thill M and Schmidt M. Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer. *Ther Adv Med Oncol* 2018; 10: 1-12. DOI: 10.1177/1758835918793326

In the article ‘Management of adverse events during CDK 4/6 inhibitor-based treatment in breast cancer’, the data in the ‘Results’ column for the MONALEESA-7 trial were incorrect (5<sup>th</sup> row of the table). The data should have read ‘23.8 versus 13.0 months PFS’ instead of ‘13.8 versus 13.8 months (hazard ratio 0.55)’.

Visit SAGE journals online  
[journals.sagepub.com/  
home/tam](http://journals.sagepub.com/home/tam)

 SAGE journals

This has been corrected in the PDF and HTML versions of the article.

